FebriDx® - Why FebriDx®

Reduce Antibiotic Use

Accurate (99% NPV)

Lower Healthcare Costs

Bacterial or Viral Infection?

The symptoms can be very similar.

Acute respiratory infections, causing symptoms such as sore throat, cough, congestion and runny nose are the most common reason for physician office visits and antibiotic prescriptions.1-3 Clinical diagnosis can be challenging due to an overlap in signs and symptoms of bacterial and viral infections.

The majority of acute respiratory infections are caused by viruses and do not require antibiotics, yet antibiotics are prescribed in up to 58% of cases and only required in approximately 11% of cases.4-5 Antibiotic resistance continues to remain a major global health threat contributing to more than 700,000 deaths worldwide.6

WHAT IF
THERE WAS A
RAPID TEST TO
DIFFERENTIATE
BACTERIAL FROM
VIRAL INFECTIONS?

97-99%
NPV7

FebriDx® is a rapid point-of-care test that uses a fingerstick blood sample to detect and aid in differentiating bacterial from viral acute respiratory infection in 10 minutes. Knowing whether a patient has a viral or bacterial infection may have a direct impact on reducing unnecessary antibiotic prescriptions, limiting the spread of antibiotic-resistant bacteria and helping providers know when to initiate treatment.

Increase confidence in decision making
Confidently rule out a bacterial infection with 97-99% negative predictive value (NPV)7 and ensure serious infections are not overlooked

Improve patient satisfaction
Gain patient acceptance of their treatment plan by offering a tangible test result

Enable improved patient management
Actionable results in 10 minutes for use during a patient visit

Support antimicrobial stewardship
Reduce unnecessary antibiotic use8-10

Acute Respiratory Infections Create Challenges. FebriDx Provides Solutions.

FebriDx First

Using a rapid screening test during a patient visit can help guide appropriate patient management and optimize practice workflow.

FebriDx results are available in 10 minutes, allowing the clinician to provide a timely and targeted treatment plan during the initial office visit.

Improve Patient Management With a FebriDx First Workflow

•FebriDx is not intended to diagnose any specific bacteria or virus, including SARS-CoV-2.

•The test is intended for professional use and should be used in conjunction with other clinical evidence including laboratory, radiographic, and epidemiological information.

•Negative results do not preclude respiratory infection and should not be used as the sole basis for diagnosis, treatment, or other clinical and patient management decisions. In addition to utilizing radiography and clinical presentation to aid in diagnosis, additional laboratory testing (e.g., bacterial and viral culture, immunofluorescence, and polymerase chain reaction [PCR]) may be used to confirm the presence of a specific respiratory pathogen.

1. Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults. Ann Intern Med. 2016;165(9):674.

2. Renati S, Linder J. Necessity of office visits for acute respiratory infections in primary care. Fam Pract 2016;33(3):312-17.

3. https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2018-namcs-web-tables-508.pdf

4. Dick K, Schneider J. Economic Evaluation of FebriDx®: A novel rapid, point-of-care test for differentiation of viral versus bacterial acute respiratory infection in the United States. JHEOR 2021;8(2)68-74.

5. Palms DL, Hicks LA, Bartoces M, et al. Comparison of antibiotic prescribing in retail clinics, urgent care centers, emergency departments, and traditional ambulatory care settings in the United States. JAMA Intern Med 2018;178(9):1267-9.

6. O’Neill, J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations; The Review on Antimicrobial Resistance: London, UK, 2014.

7. Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med 2018;50(5):420-9.

8. Davidson M. FebriDx Point-of-Care Testing to Guide Antibiotic Therapy for Acute Respiratory Tract Infection in UK Primary Care: A Retrospective Outcome Analysis. J Infect Dis Preve Med 2017;5(3):1000165.

9. Onrubia X, Gonzales IJ. A pilot evaluation of the FebriDx test in an outpatient pediatric clinic. Clin Med Invest 2020;5:1-5.

10. Carlton HC, Savovic J, Dawson S, et al. Novel point-of-care biomarker combination tests to differentiate acute bacterial from viral respiratory tract infections to guide antibiotic prescribing: a systematic review. Clin Microbiol Infect 2021;27:1096-1108.